Going Public: The IPO, the Direct Listing, and What Is Left of the SPAC

Document type: Article Practice area: Corporate — Securities Jurisdiction: United States (federal) Last reviewed: 5 September 2026

What going public actually is

It is the moment a company accepts near-strict liability for every material statement in a long document, in exchange for a market in its shares.

That framing explains almost everything about the process — why diligence is exhaustive, why the underwriters' counsel behaves as they do, why comfort letters exist, why the drafting sessions take weeks, and why experienced securities lawyers care much more about the risk factors than about the valuation.

The financing is the part everyone discusses. The liability is the part that structures the work.

The registration architecture

Section 5 of the Securities Act, 15 U.S.C. § 77e makes it unlawful to sell a security in interstate commerce unless a registration statement is in effect, and unlawful to offer one before a registration statement is filed. Section 6 governs registration; Section 10 prescribes what a prospectus must contain; and the disclosure content itself comes from the Commission's rules — principally Regulation S-K, 17 C.F.R. Part 229, for narrative disclosure, and Regulation S-X, 17 C.F.R. Part 210, for financial statements.

The registration statement on Form S-1 is the document. It contains the prospectus — business, risk factors, use of proceeds, capitalization, dilution, management's discussion and analysis, management and executive compensation, related party transactions, principal stockholders, description of capital stock — plus Part II information, exhibits, and the financial statements.

Then the Exchange Act obligations attach. Section 12(b), 15 U.S.C. § 78l, registers the class for exchange listing, and Section 13, 15 U.S.C. § 78m, begins the periodic reporting that continues indefinitely.

Section 11, and why the process looks the way it does

Section 11 of the Securities Act, 15 U.S.C. § 77k, is the reason for the diligence.

The claim. If a registration statement, when it became effective, contained an untrue statement of a material fact or omitted a material fact required to be stated or necessary to make the statements not misleading, any person acquiring the security may sue.

Against whom. Every person who signed the registration statement; every director; every person named as about to become a director; every accountant, engineer, appraiser, or other professional who consented to being named as having prepared or certified part of it; and every underwriter.

What the plaintiff need not prove. Scienter. Reliance, in the ordinary case. And — subject to the tracing requirement discussed below — much beyond the misstatement and the purchase.

The defenses. The issuer is essentially liable without fault. Everyone else may assert the due diligence defense: that after reasonable investigation they had reasonable ground to believe, and did believe, that the statements were true and there was no material omission — with a lower standard for expertised portions, chiefly the audited financial statements, where a non-expert need only have had no reasonable ground to believe them untrue.

That defense is the process. The diligence sessions, the management presentations, the site visits, the backup binders, the comfort letters from the auditors, the legal opinions, the 10b-5 negative assurance letters — all of it exists to build the record that supports a due diligence defense for the directors and the underwriters. Understanding that makes the sequence intelligible rather than ritualistic.

Section 12 — 15 U.S.C. § 77l — supplies parallel liability for offers or sales by means of a prospectus or oral communication containing a material misstatement, with a reasonable care defense under § 12(a)(2).

Limitations are in 15 U.S.C. § 77m: one year after discovery of the untrue statement or omission, or after it should have been discovered with reasonable diligence, and in no event more than three years after the security was bona fide offered to the public.

And Rule 10b-5 remains available, under Section 10(b), 15 U.S.C. § 78j, for statements outside the registration statement — with the pleading and procedural constraints of the Private Securities Litigation Reform Act at 15 U.S.C. § 78u-4 and the forward-looking statement safe harbors at 15 U.S.C. § 77z-2 and 15 U.S.C. § 78u-5.

What Omnicare requires of opinions

Prospectuses are full of statements of opinion and belief — that the company complies with applicable law, that its contracts are enforceable, that its intellectual property is adequate.

Omnicare, Inc. v. Laborers District Council Construction Industry Pension Fund, 575 U.S. 175 (2015) explains how § 11 applies to them.

A sincere statement of pure opinion is not an untrue statement of material fact merely because the opinion turns out to be wrong. If the issuer genuinely believed it, the statement was true as a statement of belief.

But an opinion can be actionable in two ways. It is untrue if the speaker did not actually hold the belief. And — the part that matters most in practice — an opinion may be actionable as an omission if it omits material facts about the issuer's inquiry into or knowledge concerning the opinion, and those facts conflict with what a reasonable investor would take from the statement itself. An issuer that says "we believe our conduct complies with the law" while its lawyer has told it otherwise, and does not disclose that, has a problem.

The practical consequences for drafting are concrete. Say who holds the belief and on what basis. Disclose the material contrary facts and the limits of the inquiry. Avoid opinions the company cannot support with a documented process. And ensure that what the company says it believes matches what its files show it was told.

A running example

Aldergate Robotics makes warehouse automation systems. Revenue of $240 million growing at 45%, gross margin of 58%, a concentrated customer base — its top three customers were 39% of revenue — and a founder-controlled board.

Its general counsel, Nkechi Vasquez-Lindholm, ran the readiness assessment eighteen months before the intended filing. Three findings shaped everything.

The financial statements were not auditable to the required standard. Aldergate had reviewed rather than audited statements for the earlier years, revenue recognition on multi-element arrangements had been applied inconsistently, and the close took thirty-one days. Fixing that took fourteen months, a new controller, two additional accountants, and a restatement of two prior periods that nobody outside the company ever saw because the work was done before filing.

The capitalization records had gaps. Eleven option grants over four years had been approved by written consent that could not be located, and two early stock issuances lacked board authorization. Curative resolutions, ratification, and — for two former employees — negotiated releases took four months and cost less than $200,000, which is a fraction of what the same problem costs when discovered during underwriter diligence.

Customer concentration was the real disclosure problem. Three customers, 39% of revenue, on contracts terminable on ninety days' notice. That was going to be a risk factor, an MD&A discussion, and a question at every investor meeting. Aldergate spent a year diversifying — not because of the offering, but the offering made the board finally do it. At filing, the top three were 27%.

The process itself. Organizational meeting in month 15. Confidential submission as an emerging growth company in month 17, with two years of audited financials. Two rounds of Commission comments, principally on revenue recognition disclosure and on the specificity of certain risk factors. Public filing in month 21. Road show and pricing in month 22.

One drafting fight worth recording. Management wanted to say "we believe our intellectual property portfolio adequately protects our core technology." Counsel asked what the belief rested on. It rested on nothing — no freedom-to-operate analysis had ever been done, and two competitors held patents the engineering team had privately worried about. Under Omnicare, an opinion that omits material facts about the inquiry behind it can be actionable as an omission. The sentence came out; a specific, accurate description of the portfolio and its limits went in.

Vasquez-Lindholm's assessment: "The offering took seven weeks. Getting ready took fourteen months, and every single problem we fixed in that period would have surfaced in underwriter diligence at ten times the cost and with the timetable already public."

The three routes

The underwritten initial public offering

The traditional structure. Underwriters purchase shares from the issuer and resell them to investors, having built a book of demand through marketing and having set a price the night before trading begins.

What the issuer gets: primary capital, price certainty at pricing, a syndicate with an incentive to support the aftermarket, research coverage, and — not trivially — a diligence process that produces a defensible record.

What it costs: the gross spread, typically the largest single expense; dilution at a price the issuer does not set; a lockup on existing holders; and a process measured in months.

The liability structure is the most tested of the three. Underwriters are § 11 defendants with a due diligence defense, and their incentive to conduct real diligence is the issuer's protection as much as their own.

The direct listing

The company registers shares for resale and lists them; existing holders sell into the market at prices set by an opening auction. Newer structures permit a primary capital raise alongside.

What it offers: no underwriting spread, no lockup in the traditional form, no dilution where no primary shares are sold, and a market-set opening price.

What it lacks: underwriters with capital at risk, a built book of institutional demand, and price certainty. A financial adviser assists but does not underwrite, which has consequences for diligence intensity and for who is a § 11 defendant.

And the liability question that hung over the structure has been answered. Slack Technologies, LLC v. Pirani, 598 U.S. 759 (2023) held that a § 11 plaintiff must plead and prove that they purchased shares traceable to the allegedly defective registration statement. In a direct listing where registered and unregistered shares begin trading simultaneously, a purchaser generally cannot establish that their shares came from the registered pool — which substantially narrows § 11 exposure in that structure.

Do not read that as an absence of liability. Section 12 claims and Rule 10b-5 claims remain, and the Court expressly declined to resolve the analogous tracing question under § 12. The practical effect is a meaningful reduction in one category of exposure, not immunity — and it does not reduce the diligence a board should want.

The de-SPAC

A special purpose acquisition company raises capital in its own public offering, holds it in trust, and then merges with a private operating company, which thereby becomes public.

Why it was attractive: speed, a negotiated valuation rather than a marketed one, the ability to use projections in the merger proxy, and access for companies that would struggle in a traditional process.

What changed. Redemptions frequently left far less cash than the trust suggested, making the "certainty" illusory. Sponsor promote and dilution were poorly understood by investors and, in several cases, inadequately disclosed. Enforcement attention focused on projections, conflicts, and the adequacy of disclosure. The Commission adopted rules addressing de-SPAC disclosure, alignment of the transaction's treatment with that of a traditional offering in defined respects, and the availability of the projections safe harbor. And the litigation followed, including fiduciary duty claims in Delaware over sponsor conflicts.

What remains. The structure still exists and is still used, in a smaller and more disciplined market. The analysis for a target should now be: what is the realistic post-redemption cash; what does the sponsor promote actually cost the company's shareholders; what diligence has been done and by whom; and whether the projections can survive the scrutiny they will receive.

And the target should understand that it is becoming a public company on someone else's timetable — with the reporting, control, and governance obligations arriving whether or not it is ready.

Building the S-1

The organizing documents are the business section, the risk factors, and management's discussion and analysis. Everything else is assembly.

The business section describes what the company does, its market, its competition, its customers, its operations, its intellectual property, its regulatory environment, and its employees. It is drafted by the company and rewritten by counsel until it is accurate rather than promotional — the most common first-draft problem is marketing language that cannot be supported.

Risk factors must be specific to the company. Generic risks, boilerplate, and hypothetical framing of risks that have already materialized are the recurring defects. If a customer has already given notice, the risk factor cannot say "we may lose customers."

Management's discussion and analysis explains the financial statements: results of operations with the reasons for changes, liquidity and capital resources, contractual obligations, critical accounting estimates, and — importantly — known trends and uncertainties reasonably likely to have a material effect. That last requirement catches issuers who disclose what happened but not what they know is coming.

Financial statements under Regulation S-X: audited statements for the required periods, prepared by an independent registered public accounting firm under the applicable auditing standards, plus interim statements as required and, where an acquisition has occurred or is probable, the target's financials and pro formas. This is the long pole in most first-time offerings, and the most common cause of delay is discovering that historical financials are not auditable to the required standard.

Then the rest: use of proceeds, capitalization, dilution, executive compensation, related party transactions, principal and selling stockholders, description of capital stock, shares eligible for future sale, tax considerations, underwriting, and legal matters — plus the exhibits, which include the material contracts the company must now make public.

Emerging growth companies and confidential submission

The accommodations available to a qualifying emerging growth company materially change the process.

Scaled disclosure: two years of audited financial statements rather than three in the registration statement; reduced executive compensation disclosure; and relief from certain accounting standard transition requirements.

Reduced ongoing obligations for a transition period, including exemption from the auditor attestation on internal control over financial reporting.

Confidential submission. The draft registration statement may be submitted non-publicly for Commission review, with public filing required a defined period before the road show. This is now used almost universally, and it is genuinely valuable: it permits the comment process to run without competitors, customers, and employees reading the company's financials, and it preserves optionality if market conditions deteriorate.

Testing the waters. Communications with qualified institutional buyers and institutional accredited investors before or after filing, to gauge interest — an accommodation since extended beyond emerging growth companies.

Research. Analyst research is permitted in circumstances that would otherwise be constrained.

The trade-off is that scaled disclosure is visible to investors, and some issuers choose to provide more than required. That is a market decision, not a legal one, and it should be made deliberately rather than by default.

Communications: the quiet period and gun jumping

The offering process constrains what the company may say, and the constraints surprise executives.

Before filing, § 5(c) prohibits offers. An "offer" is construed broadly and includes conduct conditioning the market — enthusiastic press coverage arranged by the company, an unusual publicity campaign, a founder's interview about prospects. The remedy for a violation is a cooling-off period that delays the offering, which is why counsel gets nervous about media in the months before filing.

Safe harbors exist for regularly released factual business information and forward-looking information consistent with past practice, and for communications more than a defined period before filing. The practical rule is: keep doing what you have always done, at the same cadence, and change nothing because of the offering.

Between filing and effectiveness, the preliminary prospectus is the permitted written offer; the statutory prospectus requirements in § 10 govern; and free writing prospectuses are permitted subject to conditions including filing.

The road show is oral offering activity, and what is said in it must be consistent with the prospectus. Deviating from the document in a management presentation is how issuers create liability that the document itself avoided.

After pricing, prospectus delivery obligations apply, and the research quiet periods of the exchanges and the underwriters' own policies constrain analyst communications.

The instruction for the whole company: one approval path for anything public, from the first organizational meeting through the end of the lockup, with a named approver and a written policy that reaches social media, conference appearances, customer communications, and recruiting materials.

Lockups, and the aftermath

The lockup restricts sales by officers, directors, and significant holders for a period after pricing — commonly 180 days, with variations and early release provisions tied to price or time. It is contractual, negotiated with the underwriters, and it is one of the terms existing holders care about most.

Early release triggers have become common and should be understood: partial release after a defined period if the price exceeds a threshold, releases tied to earnings announcements, and negotiated carve-outs for estate planning transfers, charitable gifts, and 10b5-1 plan adoption.

Then the public company obligations begin, and they begin immediately:

Periodic and current reporting under § 13 — annual, quarterly, and current reports on the events that require them.

Internal control over financial reporting, with management's assessment and, after the transition period, auditor attestation.

Disclosure controls and procedures, and the certifications that go with them.

Section 16 reporting by officers, directors, and ten percent holders, with the short-swing profit rules that catch people who did not know they applied.

Regulation FD, which prohibits selective disclosure of material non-public information — 17 C.F.R. Part 243 — and which changes how the company talks to investors and analysts permanently.

Insider trading compliance, blackout periods, pre-clearance, and 10b5-1 plans.

Exchange listing standards, including board independence, committee composition, audit committee financial expertise, and governance requirements.

And the litigation exposure that begins with the first stock drop. A company that misses guidance in its second quarter as a public company should expect a securities class action, and the defense of it will turn on the disclosure and the process behind it — which is why the readiness work matters more than the offering.

What to tell the board

One: this is a liability event with a financing attached. Section 11 imposes near-strict liability on the issuer and reaches every director who signs. The diligence, the drafting sessions, and the comfort letters exist to build the due diligence defense for everyone else.

Two: readiness takes a year, and the offering takes weeks. Auditable financials, a public-company close process, clean capitalization records, and functioning internal control are the long poles — and every problem fixed quietly beforehand costs a fraction of the same problem found in underwriter diligence.

Three: what you say between now and the end of the lockup is regulated. One approval path, one named approver, and no change in publicity cadence because of the offering.

Four: opinions are actionable if you did not hold them or if you omit what you knew. After Omnicare, "we believe" is not a shield. Say what the belief rests on, or do not say it.

Five: several governance choices made in the final weeks last for decades — dual class and its sunset, board classification, forum provisions, indemnification and the D&O tower. Decide them deliberately.

Six: pricing is your decision, not a ratification. Price, size, and the trade-off between proceeds and aftermarket performance belong to the board.

Seven: the obligations start immediately — reporting deadlines, internal control assessments, Regulation FD, Section 16, insider trading controls, and a proxy season. A company that is not operationally ready for a quarterly close will discover it in public.

And eight: not every company should be public. The cost, the cadence, the disclosure competitors will read, and the exposure to securities litigation are permanent. Counsel who says so before the process begins is worth more than counsel who runs a beautiful offering for a company that should have stayed private.

Life as a public company, from day one

The obligations that begin at effectiveness are the part boards understand least and live with longest.

The reporting calendar under Section 13, 15 U.S.C. § 78m runs continuously: annual and quarterly reports on a filing deadline determined by filer status, and current reports triggered by specified events on a short fuse. A company whose close takes three weeks cannot meet a quarterly deadline that assumes it takes one.

Internal control over financial reporting, with management's assessment from the first annual report after the offering and — after the emerging growth company transition — auditor attestation. Material weaknesses are disclosable and are read as a signal about management.

Disclosure controls and the certifications, which make the chief executive and chief financial officer personally responsible for the accuracy of what is filed.

Regulation FD at 17 C.F.R. Part 243 prohibits selective disclosure of material non-public information to market professionals and holders. It permanently changes how the company talks to analysts and investors, and the most common violation is a well-meaning executive answering a question in a one-on-one meeting.

Section 16 reporting by officers, directors, and ten percent holders, with the short-swing profit rule that catches people who did not know it applied — including on routine transactions in a company plan.

Insider trading compliance: a policy, blackout periods, pre-clearance, and 10b5-1 plans adopted during open windows and observing the applicable cooling-off periods.

Exchange listing standards — board and committee independence, audit committee financial expertise, annual meetings, shareholder approval requirements for equity issuances and plans, and continued listing criteria.

Proxy season, which arrives faster than expected: the annual meeting, say-on-pay, the compensation discussion and analysis, and the proxy advisory firms whose recommendations move votes.

And the first stock drop. A company that misses guidance in an early quarter should expect a securities class action, and its defense will rest on what was disclosed, when, and on the process that produced it. That is why the disclosure committee, the earnings script review, and the guidance policy should be operating before the first quarter closes — not after the complaint arrives.

Choosing among the routes

The comparison that matters to a board, stated on its own terms.

Capital. An underwritten offering raises primary capital at a price set by a book. A traditional direct listing raises none, though primary structures now exist. A de-SPAC raises whatever survives redemptions — which is the term that has most often disappointed.

Price certainty. Underwriters commit at pricing. A direct listing's opening price is set by an auction with no book behind it. A de-SPAC's valuation is negotiated in the merger agreement, which is certainty about the number and not about the cash.

Cost. The gross spread is the largest expense in an underwritten deal. A direct listing avoids it and pays advisory fees. A de-SPAC's cost is the sponsor promote and the associated dilution, which is larger than it looks and is borne by the target's shareholders.

Liability. The underwritten offering has the most-tested structure, with underwriters as § 11 defendants whose diligence protects everyone. The direct listing has materially narrower § 11 exposure after Slack Technologies, LLC v. Pirani, 598 U.S. 759 (2023) because of the tracing requirement — but retains § 12 and Rule 10b-5 exposure. The de-SPAC's disclosure now sits closer to a traditional offering than it once did, and projections receive scrutiny.

Speed. A de-SPAC was historically faster; the gap has narrowed considerably.

Shareholder base. An underwritten offering lets the underwriters build one deliberately. A direct listing takes whoever buys. A de-SPAC inherits the SPAC's holders, less those who redeem.

Existing holders. A direct listing gives them immediate liquidity with no traditional lockup. An underwritten offering locks them up. Founders and early investors care about this more than about anything else on this list.

The honest recommendation for most companies is still the underwritten offering, for a reason that is not about mechanics: the process itself — the diligence, the drafting sessions, the comment letters — produces a better document and a defensible record. Companies that go public through routes with lighter process reach the market faster and meet their first securities complaint less prepared.

Pricing, allocation, and the days around it

The mechanics of the final week are opaque to most first-time issuers and worth understanding, because several decisions belong to the company.

The range. Set in the preliminary prospectus, informed by comparable company analysis and early investor feedback. It is a marketing device as much as a valuation, and a range set too high invites a downward revision that reads as a failure.

The road show. Management presents to institutional investors over roughly a week, in person, virtually, or both. What is said must be consistent with the prospectus — deviating in a meeting is how issuers create liability the document itself avoided. Record what is said and keep the deck.

Building the book. Underwriters collect indications of interest, with quantity and price limits, and assess demand. The book is the underwriters' information, and the issuer sees a summary rather than the detail.

Pricing. The night before trading, the issuer's board — usually a pricing committee — approves the price and the size. This is a real decision, not a ratification. Pricing below the range to secure a strong aftermarket, pricing at the top to maximize proceeds, and increasing or decreasing the size are all choices with consequences, and the company should understand the trade-offs rather than accepting a recommendation.

Allocation is the underwriters' function, and it shapes the shareholder base for years. The issuer has a legitimate interest in the quality and stickiness of the investors allocated, and can express it — though it does not control the outcome.

The underwriting agreement is signed at pricing. Its material terms: the firm commitment, the gross spread, the over-allotment option permitting the underwriters to purchase additional shares to cover short positions, representations and warranties by the issuer, conditions to closing including the comfort letter bring-down and the legal opinions, indemnification of the underwriters by the issuer, and contribution provisions.

Then the market-out clause, which permits the underwriters to terminate in defined circumstances between pricing and closing. It is rarely invoked and it is not nothing.

Closing occurs a short period after pricing, with delivery of shares against payment, the bring-down comfort letter, and the final opinions.

And the aftermarket. Stabilization activity is permitted within defined limits, the over-allotment option is exercised or expires, research quiet periods run, and the lockup clock starts. The company's first earnings report as a public company is the next event that matters, and preparation for it should already be underway.

Governance decisions made at the offering that last for decades

Several structural choices are made once, in the weeks before pricing, and are extremely difficult to change afterward.

Dual-class capital structure. A high-vote class for founders preserves control and is accepted by the market in some sectors and resisted in others. The considerations: index eligibility, which excludes or limits some dual-class issuers; institutional investor policies and the proxy advisory firms' positions; and whether to include a sunset — time-based, ownership-based, or transfer-based. A structure without a sunset is harder to justify each year it persists.

Board composition and staggering. A classified board is a defensive measure and a governance negative in the eyes of many investors. Newly public companies frequently adopt one and unwind it under pressure within a few years, which is worse than either choice made once.

Charter defenses. Exclusive forum provisions for internal corporate claims and, separately, for Securities Act claims — the latter now permitted in Delaware charters and worth considering given § 11 exposure. Advance notice bylaws. Supermajority requirements. Written consent and special meeting rights. Each is easier to adopt before the offering than after.

Controlled company status. Where a founder or group holds majority voting power, exchange rules permit exemptions from certain independence requirements. Taking the exemption is permissible and is noticed.

Indemnification and D&O insurance. Charter and bylaw indemnification to the fullest extent permitted, indemnification agreements with each director and officer, and a public company D&O program placed before the road show — because the offering itself is the covered event, and the Side A tower is what individual directors care about.

Equity plan design. An evergreen provision, the initial share reserve, and the treatment of pre-offering awards. Sized wrong, this becomes an annual dilution fight.

And the choice of exchange and of state of incorporation, both of which carry substantive consequences and both of which are frequently decided by default.

The Commission review, and the comment process

Between filing and effectiveness sits a review that first-time issuers consistently underestimate.

How it works. The staff reviews the registration statement and issues written comments — typically the first round within thirty days of an initial filing. The issuer responds in writing, amends the registration statement, and the process repeats until the staff has no further comments. Two to four rounds is ordinary for a first-time issuer.

What the comments are about. Revenue recognition and the adequacy of its disclosure. Non-GAAP measures, their prominence relative to GAAP measures, and the reconciliations. The specificity of risk factors. Management's discussion and analysis, particularly the discussion of known trends and uncertainties — the requirement issuers most often address thinly. Segment reporting. The treatment of an acquisition and whether target financial statements and pro formas are required. And the basis for any claim of market position or market size.

How to respond well. Answer every comment, in a numbered response letter, either by making the change or by explaining precisely why no change is warranted. Do not argue at length with a comment you will ultimately accept — it costs a round. And where the answer requires a judgment, say what the judgment was and what it rested on.

Timing. Each round costs two to four weeks by the time the response is prepared, the amendment is filed, and the staff reviews it. A first-time issuer should assume the review adds two to three months to the timetable and should not schedule the road show against an optimistic assumption.

Pre-filing consultation is available and underused. Where a novel accounting question, an unusual structure, or a difficult disclosure judgment exists, raising it with the staff before filing is faster than litigating it through comments.

And confidential submission changes the experience considerably. The comment process runs before anything is public, so a difficult exchange about revenue recognition does not become a news story, and an issuer that decides to postpone has revealed nothing.

The working group, and what each party is doing

An offering is run by a group whose members have genuinely different interests, and understanding that makes the process legible.

The issuer wants to raise capital at a good price, disclose the minimum consistent with the law, and get back to running the business.

Issuer's counsel drafts the registration statement, manages the process, and protects the company and its directors — which frequently means insisting on disclosure the business does not want.

The underwriters want a deal that prices and trades well, because their reputation and their aftermarket position depend on it. They also want a due diligence record, because they are § 11 defendants.

Underwriters' counsel builds that record. The diligence questions that feel adversarial are not hostility; they are the defense being assembled, and it protects the issuer's directors too.

The auditors deliver the audit opinion and the comfort letter — negative assurance on unaudited financial information and agreed-upon procedures tying numbers in the prospectus back to the accounting records. The comfort letter's scope is negotiated, and the tick-and-tie exercise is where prospectus numbers get corrected.

The financial printer manages filing and typesetting, and is more central to the timetable than anyone expects.

Then the deliverables that close the diligence loop: legal opinions from issuer's and underwriters' counsel; 10b-5 negative assurance letters stating that nothing has come to counsel's attention causing them to believe the registration statement contained a material misstatement or omission; officer certificates; and the comfort letters, brought down at pricing and closing.

The drafting sessions. The whole group in a room, reading the document aloud, line by line, for days. It is tedious and it is the point: it forces every party to hear every sentence and object. The problems found in drafting sessions are the ones that do not become claims.

Readiness: the year before

The companies that go public well are the ones that started preparing eighteen months earlier.

Financial reporting. Auditable historical financials under the required standards, a close process that produces reliable numbers on a public company timeline, and the accounting personnel to run it. This is the most common cause of delay and the hardest to fix quickly.

Internal control. Documented processes, tested controls, and remediated deficiencies. Material weaknesses disclosed in a registration statement are survivable and expensive.

Corporate housekeeping. Clean capitalization records, all equity issuances documented and properly authorized, option grants correctly priced and approved, stockholder agreements terminated or amended to survive the offering, and charter and bylaws in public company form.

Governance. Independent directors recruited, an audit committee with a financial expert, compensation and nominating committees, and the policies a public company must have — code of conduct, insider trading, disclosure, related party transactions, and clawback.

Contracts. Material agreements identified, reviewed for change-of-control and confidentiality provisions that will complicate public filing, and — where necessary — renegotiated before they must be filed as exhibits.

Compensation. Equity plans sized for a public company, executive arrangements reviewed, and the disclosure consequences understood by the people whose compensation will be published.

Legal and regulatory. Litigation assessed and disclosed, regulatory compliance documented, intellectual property ownership confirmed and chain of title cleaned.

And the honest conversation. Not every company should be public. The reporting burden, the cost, the disclosure of information competitors will read, the quarterly cadence, and the exposure to securities litigation are permanent. A company with lumpy results, a concentrated customer base, or a business plan that requires patience is frequently better served by remaining private — and counsel who says so before the process starts does the client more good than counsel who runs a beautiful offering.